Biopmedical is a Finalist in the mHealth Israel Startup Contest, Biopmedical can identify cancerous cells in epithelial tissue, offering standard colposcope capabilities with state-of-the-art, enhanced features. The novel device combines advanced, high-resolution optics with integrated micro and macro cameras and other optical elements to produce highly sensitive optical signatures for automatic identification of suspicious areas. The collected data is combined and analyzed using Biop’s proprietary algorithm. Preliminary commercialization of Biop’s proprietary transducer will supplement or replace current colposcopy technologies.

1. © 2016 Biopmedical Ltd. All rights reserved.
Biopmedical
Improved identification of cancerous cells
Biopmedical Ltd.
Oholiav 10
Ramat Gan, Israel
www.biopmedical.com
Ilan Landesman, CEO
Mobile: +972.54.669.8512
ilan@biopmedical.com
Background
Cervical cancer is the second most common cancer among women worldwide.
Approximately 6% of cytology tests return with abnormal findings and are referred to
follow-on screening; namely, colposcopy, the gold standard for cervical cancer
screening. Unfortunately, colposcopies are severely limited. They are not sensitive to
precancerous conditions, are not objective, and have a high rate of false positive and
negative. In only a small minority of these cases is cervical cancer confirmed.
The result: Thousands of unnecessary colposcopies and a long complicated screening
process (from Pap test to biopsy results).
The Technology
Biopmedical has developed an innovative
technology for identifying cancerous cells in
epithelial tissue.
Biop’s real-time screening tool offers standard
colposcope capabilities with state-of-the-art,
enhanced features. The novel device combines
advanced, high-resolution optics with
integrated micro and macro cameras and other
optical elements to produce highly sensitive
optical signatures for automatic identification of
suspicious areas and quantification of the
cancer stage.
The collected data is combined and analyzed
using Biop’s proprietary algorithm. Preliminary commercialization of Biop’s proprietary
transducer will supplement or replace current colposcopy technologies.
The Advantages
 Enables diagnosis of cancer and pre-cancerous tissues
 Automatically scans entire cervix for point-of-care diagnosis
 Generates a real-time map of the cervix for accurate biopsy, when necessary
 Eliminates dependency on operator proficiency due to software analysis
 Reduces the wait time (and associated anxiety) between testing and diagnosis
 Generates data sets for “big data”
The Market
Of the 55 million Pap tests performed every year in the United States, approximately
3.5 million (6%) return abnormal results and require further testing. More than 450,000
cases of cervical cancer are diagnosed each year, resulting in 250,000 deaths.
Biop targets a $2 billion cervical cancer screening market and a $375 million annual
market in the adjunctive colposcopy market.
Business Strategy
Preliminary sales will be in the United States, where regulatory and reimbursement
approvals of the system are straightforward, enabling easy access in this large market.
Biop’s device will significantly improve screening and diagnosing cervical cancer for
women in developing countries. Biop will partner with philanthropic organizations to
bring the promise of simple, effective diagnosis to regions where cervical cancer
remains a leading cause of mortality.
Status
Founded: 2013
Investors: SCI & private investors
IP: PCT submitted (during national
phase)
Regulation: Fast route to FDA
510(k),
Highlights:
Finalist in 2014 Cleveland clinic
challenge Summit
2014 IBM accelerator member and
selected as the best company in
IBM Alpha Zone accelerator
Finalist at Mhealth Israel
competition
90% sensitivity in clinical trials.
Working probe is currently during
clinical study in big medical center
in Europe
Road map:
FDA submission Q1 2017
commercial product and U.S. sales
Q3 2017
Status
Biopmedical completed the A
round
Named Sid Braginsky as
Chairman
Biop’s real-time screening tool for
cancer cells in epithelial tissue